RBM10 and neoplasm: The clinical data of 572 patients included in the TCGA database (including gender, age, the clinical stage of the tumor, and whether there was distant metastasis) were divided into high- and low-risk groups according to the expression level of RBM10, and the independent predictive efficacy was evaluated.